BRAINSWAY LTD-ADR (BWAY) Stock Price, Forecast & Analysis
USA - NASDAQ:BWAY - US10501L1061 - ADR
BWAY Key Statistics, Chart & Performance
The current stock price of BWAY is 15.76 USD. In the past month the price decreased by -1.5%. In the past year, price increased by 72.81%.
BWAY Latest News, Press Relases and Analysis
BWAY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 26.17 | 227.29B | ||
| ISRG | INTUITIVE SURGICAL INC | 63.82 | 196.99B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.81 | 152.16B | ||
| SYK | STRYKER CORP | 27.5 | 138.48B | ||
| IDXX | IDEXX LABORATORIES INC | 54.71 | 55.19B | ||
| BDX | BECTON DICKINSON AND CO | 13.39 | 55.33B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.58 | 50.67B | ||
| RMD | RESMED INC | 24.69 | 35.68B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.94 | 33.40B | ||
| DXCM | DEXCOM INC | 31.22 | 22.77B | ||
| PODD | INSULET CORP | 72.8 | 23.42B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.11 | 17.81B |
Related stock screener links
About BWAY
Company Profile
Brainsway Ltd. engages in the development and sale of non-invasive neurostimulation treatments using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The firm primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.
Company Info
BRAINSWAY LTD-ADR
16 Hartum Street Rad Tower, 14Th Floor, Har HaHotzvim
JERUSALEM 9777518 IL
CEO: Christopher R. von Jako
Employees: 120
Phone: 97225813140
BRAINSWAY LTD-ADR / BWAY FAQ
What does BWAY do?
Brainsway Ltd. engages in the development and sale of non-invasive neurostimulation treatments using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The firm primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.
What is the current price of BWAY stock?
The current stock price of BWAY is 15.76 USD. The price decreased by -1.56% in the last trading session.
Does BRAINSWAY LTD-ADR pay dividends?
BWAY does not pay a dividend.
How is the ChartMill rating for BRAINSWAY LTD-ADR?
BWAY has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Can you provide the PE ratio for BWAY stock?
The PE ratio for BRAINSWAY LTD-ADR (BWAY) is 15.45. This is based on the reported non-GAAP earnings per share of 1.02 and the current share price of 15.76 USD.
Can you provide the market cap for BRAINSWAY LTD-ADR?
BRAINSWAY LTD-ADR (BWAY) has a market capitalization of 299.50M USD. This makes BWAY a Micro Cap stock.
What is the outstanding short interest for BRAINSWAY LTD-ADR?
The outstanding short interest for BRAINSWAY LTD-ADR (BWAY) is 0.95% of its float.
BWAY Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to BWAY. When comparing the yearly performance of all stocks, BWAY is one of the better performing stocks in the market, outperforming 92.44% of all stocks.
BWAY Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to BWAY. BWAY has an excellent financial health rating, but there are some minor concerns on its profitability.
BWAY Financial Highlights
Over the last trailing twelve months BWAY reported a non-GAAP Earnings per Share(EPS) of 1.02. The EPS increased by 223.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 11.6% | ||
| ROA | 4.79% | ||
| ROE | 7.84% | ||
| Debt/Equity | 0.08 |
BWAY Forecast & Estimates
7 analysts have analysed BWAY and the average price target is 0.11 USD. This implies a price decrease of -99.28% is expected in the next year compared to the current price of 15.76.
For the next year, analysts expect an EPS growth of 58.83% and a revenue growth 15% for BWAY